<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="listed in Table 3. Long-term moderate-to-high dose corticosteroid therapy (oral" exact="prednisone" post="≥ 10 mg/day over 4 weeks) increases the risk"/>
 <result pre="HBsAg-negative plus anti-HBc positive [98]. Long-term, low-dose corticosteroid therapy (oral" exact="prednisone" post="of less than 10 mg/day over 4 weeks) may"/>
 <result pre="which necessitates antiviral prophylaxis. In contrast, patients receiving shortterm oral" exact="prednisone" post="over 1 week are at low risk of reactivation"/>
 <result pre="do not need antiviral prophylaxis [98]. Immunophilin inhibitors such as" exact="cyclosporine" post="and tacrolimus may increase the likelihood of HBV reactivation"/>
 <result pre="need antiviral prophylaxis [98]. Immunophilin inhibitors such as cyclosporine and" exact="tacrolimus" post="may increase the likelihood of HBV reactivation [100]. However,"/>
 <result pre="the likelihood of HBV reactivation [100]. However, patients receiving methotrexate," exact="azathioprine" post="or 6-mercaptopurine do not require antiviral prophylaxis because they"/>
 <result pre="of HBV reactivation [100]. However, patients receiving methotrexate, azathioprine or" exact="6-mercaptopurine" post="do not require antiviral prophylaxis because they are at"/>
 <result pre="before starting immunosuppressive therapy—most literature specifies 7 days before [107]." exact="Entecavir" post="and tenofovir are preferred to other antiviral agents, because"/>
 <result pre="and future directionsGastroenterology20171521297130928219691 84LoombaRRowleyAWesleyRet al.Systematic review: the effect of preventive" exact="lamivudine" post="on hepatitis B reactivation during chemotherapyAnn Intern Med200814851952818378948 85YeoWChanPKZhongSet"/>
 <result pre="after immunosuppressive or cytotoxic chemotherapyJ Gastroenterol2016511081108926943169 92XuZDaiWWuYTet al.Prophylactic effect of" exact="lamivudine" post="on chemotherapy-induced hepatitis B virus reactivation in patients with"/>
 <result pre="B core antibody-positive rheumatoid arthritis patients undergoing antitumour necrosis factor" exact="alpha" post="therapyAnn Rheum Dis2011701719172521719446 102LuciforaJXiaYReisingerFet al.Specific and nonhepatotoxic degradation of"/>
 <result pre="prevention of chemotherapy-induced hepatitis B virus reactivationOncotarget20167306423065827121321 108YangCQinBYuanZChenLZhouHYMeta-analysis of prophylactic" exact="entecavir" post="or lamivudine against hepatitis B virus reactivationAnn Hepatol20161550151127236149 109YuSLuoHPanMet"/>
 <result pre="chemotherapy-induced hepatitis B virus reactivationOncotarget20167306423065827121321 108YangCQinBYuanZChenLZhouHYMeta-analysis of prophylactic entecavir or" exact="lamivudine" post="against hepatitis B virus reactivationAnn Hepatol20161550151127236149 109YuSLuoHPanMet al.Comparison of"/>
 <result pre="lamivudine against hepatitis B virus reactivationAnn Hepatol20161550151127236149 109YuSLuoHPanMet al.Comparison of" exact="entecavir" post="and lamivudine in preventing HBV reactivation in lymphoma patients"/>
 <result pre="hepatitis B virus reactivationAnn Hepatol20161550151127236149 109YuSLuoHPanMet al.Comparison of entecavir and" exact="lamivudine" post="in preventing HBV reactivation in lymphoma patients undergoing chemotherapy:"/>
 <result pre="Clin Pharm2016381035104327450506 110CervaCColagrossiLMaffongelliGet al.Persistent risk of HBV reactivation despite extensive" exact="lamivudine" post="prophylaxis in haematopoietic stem cell transplant recipients who are"/>
 <result pre="cyclosporine)  Low risk (&amp;lt;1%) Short-term corticosteroids (≤1 week) Noa Azathioprine/6-mercaptopurine," exact="methotrexate" post="HBsAg-negative/anti-HBc-positive  High risk (≥ 10%) Not available Yes  Moderate"/>
 <result pre="low-dose corticosteroids (prednisone &amp;lt; 10 mg/day, ≥ 4 weeks) Azathioprine/6-mercaptopurine," exact="methotrexate" post="aPreemptive therapy."/>
</results>
